AcelRx Pharmaceuticals to Present at Two Upcoming Conferences
AcelRx Pharmaceuticals (Nasdaq: ACRX), a specialty pharmaceutical company, will present at two upcoming conferences: the H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
AcelRx Pharmaceuticals (Nasdaq: ACRX), a specialty pharmaceutical company, will present at two upcoming conferences: the H.C. Wainwright & Co. 22nd Annual Global Investment Conference on September 14, 2020 and the Cantor Fitzgerald Virtual Global Healthcare Conference on September 16, 2020. The management will provide business updates and participate in one-on-one investor meetings. A live webcast can be accessed via the company’s website. Replays will be available for 90 days after the events.
Details
News Market Reaction – ACRX
The recorded move for ACRX in the trading session of this news was -1.83%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
REDWOOD CITY, Calif., Sept. 10, 2020 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that management will be providing an overview of the business and company updates at the H.C. Wainwright & Co. 22nd Annual Global Investment Conference taking place September 14-16, 2020, and at the Cantor Fitzgerald Virtual Global Healthcare Conference taking place September 15-17, 2020.
Details of the events are as follows:
H.C. Wainwright & Co. 22nd Annual Global Investment Conference
Date: Monday, September 14, 2020
Presentation Time: 4:30 PM Eastern Time / 1:30 PM Pacific Time
Cantor Fitzgerald Virtual Global Healthcare Conference
Date: Wednesday, September 16, 2020
Presentation Time (Fireside Chat): 4:00 PM Eastern Time / 1:00 PM Pacific Time
A live webcast link of both of the events can be found on the Company's website at http://ir.acelrx.com/upcoming-events. Management will also be hosting one-on-one investor meetings throughout the day.
For those not available to listen to the live webcast, a replay will be archived for 90 days and available through the Investors page on www.acelrx.com.
About AcelRx Pharmaceuticals, Inc.
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. AcelRx's proprietary, non-invasive sublingual formulation technology delivers sufentanil with consistent pharmacokinetic profiles. The Company has one approved product in the U.S., DSUVIA® (sufentanil sublingual tablet, 30 mcg), known as DZUVEO in Europe, indicated for the management of acute pain severe enough to require an opioid analgesic for adult patients in certified medically supervised healthcare settings, and one product candidate, Zalviso®(sufentanil sublingual tablet system, SST system, 15 mcg) being developed as an innovatively designed patient-controlled analgesia (PCA) system for reduction of moderate-to-severe acute pain in medically supervised settings. DZUVEO and Zalviso are both approved products in Europe. Zalviso is not approved in the U.S. For additional information about AcelRx, please visit www.acelrx.com.
View original content to download multimedia:http://www.prnewswire.com/news-releases/acelrx-pharmaceuticals-to-present-at-two-upcoming-conferences-301127962.html
SOURCE AcelRx Pharmaceuticals, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.